J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug

2 hours ago 1

Healthcare

Gavel on block on a desk or table with space for copy

A U.S. appeals court has sided with Johnson & Johnson (NYSE:JNJ) in a patent dispute with Viatris (NASDAQ:VTRS) and Teva Pharmaceutical (NYSE:TEVA) over the company’s neurology drug Invega Sustenna.

The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday

Recommended For You

More Trending News

Read Entire Article

J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug

Recommended For You

More Trending News

Related

YieldMax ARKK Innovation Option Income Strategy ETF declares...

MongoDB rises after Wolfe Research starts coverage with bull...

Comtech announces COO, CTO, and CFO appointments

US tariff letter still pending; Go tapped to make announceme...

Morgan Stanley resumes coverage of Capital One Financial wit...

PHL ‘stands to benefit’ after US barely budges on region’s t...

Zambales, Pangasinan set for hydrogen resource exploration

Organic pesticide developed by D&L unit approved for cocolis...

Council announces seizure of smuggled rice in Talisay, Cebu

Prysmian shares surge as cable maker seen winning from U.S. ...

LGUs ordered to develop coastal ‘greenbelt’ zones

Ondas Holdings reports preliminary Q2 2025 financial results...

CAB seeks expanded air deal with Australia

DEPDev calls 10% tariff positive outcome, but sees retention...

CoreWeave starts offering Nvidia's RTX PRO 6000 Blackwell GP...

U.S. Army sharply expands Patriot missile procurement amid s...

PCC considering changes to divestment rules

Input VAT refund developments under CREATE MORE

YieldMax Ultra Option Income Strategy ETF declares $0.096 di...

Altice USA's unit Lightpath looks to sell asset-backed secur...

Trending

Popular

TechCrunch Mobility: The state of EV sales and Rivian secure...

Home Depot is buying GMS for about $4.3 billion as retailer ...